# **Cancer in Primary Care**

#### David Sadava, PhD

Adjunct Professor of Cancer Cell Biology City of Hope Medical Center Duarte, CA Pritzker Family Foundation Professor of Biology, Emeritus The Keck Science Center Claremont, CA

CONTINUING EDUCATION COMPANY

# Disclosure

I have no financial interests or relationships to disclose.

CONTINUING EDUCATION COMPANY

David Sadava, PhD Cancer in Primary Care

2



- A. The war on cancer
- B. Cancer screening
- C. Cancer prevention
- D. Cancer survivorship

## WAR ON CANCER

President Richard Nixon signs the National Cancer Act on December 23, 1971



David Sadava, PhD Cancer in Primary Care

## WAR ON CANCER

President Joe Biden announces Cancer Moonshot on February 3, 2022



Morbidity and mortality

Disease	World	High-income
Circulatory	1	1
Infections	2	6
Mental, behavioral	3	3
Neonatal	4	7
Cancers	5	2
Musculoskeletal	6	4
Injuries	7	5

IMHE, Seattle, 10/20

## **PEOPLE WITH CANCER, 2024**

US: excluding non-melanoma skin cancer

2,001,140 people newly diagnosed (2024 est.)


35% diagnosed less than 5 years ago


17,113,494 people living with cancer (2023 est.)


5-year survival: 70% (was 50% in 1975)

611,720 people die from cancer (2024 est.)

ACS, SEER









## CANCER 5-YEAR SURVIVAL SINCE 1975


Site	1975-77	1995-97	2013-2019
All sites	49	63	69
Breast (female)	75	87	91
Colon & rectum	50	61	64
Leukemia	34	48	67
Liver & intrahepatic bile duct	3	7	22
Lung & bronchus	12	15	25
Melanoma of the skin	82	91	94
Non-Hodgkin lymphoma	47	56	74
Ovary	36	43	51
Pancreas	3	4	13
Prostate	68	97	97
Uterine cervix	69	73	67
Uterine corpus	87	84	81


ACS/SEER





























## **CANCER SCREENING IN PRIMARY CARE**


Screening tests detect disease before it is harmful:


Success: A good test widely applied

- Cervical cancer screening is very successful
- Breast cancer screening is successful
- Colon cancer screening is successful
- Prostate cancer screening is partially successful
- Lung cancer screening is partially successful

Endpoint issue: Does detection result in improved survival?







## USPSTF:US PREVENTIVE SERVICES TASK FORCE, 2024

Michael Barry, MD (outcomes) Chair

Wanda Nicholson, MD (perinatal) Esa Davis, MD, MPH (perinatal) Tumaini Coker, MD (pediatrics) Gbenga Obedegbe, MD (health disp.) Gotham Rao, MD (cardiovascular) Carlos Jaen, MD, MPH (family med) Joel Tsevat, MD, MPH (quality of life) John Wong, MD, MPH (primary care) David Chelmow, MD (obgyn) Katrina Donohue, MD (family med) Li Li, MD, MPH (population health) Lori Pbert, PhD (prevention) Michael Silverstein (pediatrics) James Stevermer, MD, MPH (prev) Sandra Underwood, RN, PhD (health disp) John Ruiz, PhD (psychology)

CERVIC	AL CANCER S USPSTF 201	
Population	Recommendation	Evidence for screening
< 21 years	No screening	D
21-29 years	Cvt. everv 3 years	А


21-29 years	Cyt. every 3 years	А
30-65 years	Cyt. every 5 years or HPV every 5 years	А
>65 years	No screening	D
Hysterectomy with no prior lesion	No screening	D


< 21 years	No screening	
	No screening	
	/s: 19 % (2 million) females a necessary	age 15-20 annual Pap smeai
30-65 years	Cyt. every 5 years or HF	PV every 5 years
	<i>.vs. HPV</i> : HPV testing is 2x eoplasia (2018)	more sensitive in
>65 years	No screening	
California study (20	023): 17% of cervical cancer	diagnoses were in
	ally advanced disease with p	


CERVICA	AL CANCER S ACS 2023	CREENING
Population	Recommendation	Evidence for screening
< 25 years	No screening	D
25-65 years	HPV every 5 years	A
25-65 years	Cyt. every 3 years with HPV every 5 years	А
>65 years	No screening	D
Hysterectomy	No screening	D

with no prior lesion

Transition from cytology to HPV Issue: Local availability of HPV testing vs cytology








## BREAST CANCER SCREENING RECOMMENDATION 2024 USPSTF

Population	Recommendation for mammography	Evidence for screening
< 40 years	No screening unless genetic risk	D
40-74 years	Biennial	В
>75 years	No screening	I: insufficient evidence for benefit




## SCREENING FOR BREAST CANCER SUSCEPTIBILITY: MUTATIONS


*Clinical case:* 22-year-old female Mother: breast cancer age 35 Grandmother: breast cancer age 38


Analysis:

DNA sequencing for 23 genes implicated in breast cancer: *ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, DICER, EPCAM, MLH1, MSH2, MSH6, NBN, NF1, PALB2, PMS2, PTEN, RAD51C, RAD51D, RECQL, SMARCA4, STK11, TP53* 


- · Patient: Change behavior to lower risk factors
- Physician: Advise preventive care, increase screening








Screening interval age 45-75CRC lives saved / 1000 screenedFOBTAnnual26FITAnnual26FIT-DNAAnnual26
FITAnnual26
FIT-DNA Annual 26
<b>Sigmoid.</b> 5 yr 26
Colonoscopy 10 yr 27




#### COLON CANCER SCREENING RECOMMENDATION 2021 USPSTF

Population	Recommendation for screening	Evidence for screening
45-49 years	Screening as below	В
45-75 years	<i>Stool:</i> FOBT: annual FIT: annual FIT-DNA: 1-3 yr	A
45-75 years	<i>Direct visualization:</i> Sigmoid: every 5 yr Colonoscopy: every 10 yr	A
>75 years	Selectively offer screening	C: low evidence of benefit








### PROSTATE CANCER SCREENING: PSA


### The Great Prostate Mistake RICHARD J. ABLIN

EACH year some 30 million American men undergo testing for prostate-specific antigen, an enzyme made by the prostate. Approved by the Food and Drug Administration in 1994, the P.S.A. test is the most commonly used tool for detecting prostate cancer. The test's popularity has led to a hugely expensive public health disaster. It's an issue I am painfully familiar with — I discovered P.S.A. in 1970.




#### PROSTATE CANCER SCREENING RECOMMENDATION 2018 USPSTF

Population	Recommendation for PSA screening	Evidence for screening
< 55 years	No screening	D
55-69 years	Discuss: small benefit vs. harm by additional testing, over-diagnosis, treatment side effects	С
>70 years	No screening	D



	LUNG CAN		REENING
	5-year survival fo	5-year survival for breast cancer >90%	
	"	colorectal	65%
	"	prostate	>95%
	Screening detec	ts cancers whe	en localized
	"	lung	23%
	5-year survival fo	or lung cancer a	after diagnosis
	Localized: Regional: Distant spread:	60% (25% of 30% (20% of 10% (55% of	patients)
	Need test	to detect loca	lized disease
17			

## LUNG CANCER SCREENING




Low-dose CT scan:


Sensitivity 94% Specificity 95%



X-ray:


Sensitivity 73% Specificity 91%







- A. The war on cancer
- B. Cancer screening
- C. Cancer prevention
- D. Cancer survivorship



## **CAUSES OF CANCER**



Dick Powell, dir. Lung cancer



Agnes Moorhead Uterine cancer



Pedro Armendariz Kidney cancer



John Hoyt Lung cancer


Radiation cause? But they were smokers.





Susan Hayward Brain cancer





John Wayne Stomach cancer














CANCER PRE	VENTION: VAPIN
Does vaping red	duce cancer in smokers?
Surrogate end point: Does vapir	ng reduce tobacco smoking
China: 1060 smokers (10/day)	
	Quit after 6 months
Electronic cigarettes	16%
Varenicline	14%
Nicotine gum	8%
Switzerland 1246 smokers (5/day)	
	Quit after 6 months
Electronic cigarettes + counseling	29%
Counseling only control	16%
	JAMA Int Me NEJM 390: 6

## TOBACCO SMOKING CESSATION ADULTS: RECOMMENDATIONS 2021 USPSTF

Population	Recommendation	Evidence
Non-pregnant	Clinician counseling; FDA approved drugs	A
Pregnant	Clinician counseling; no drugs	А
All	E-cigarettes	I: insufficient evidence for benefit

## HUMAN TUMOR VIRUSES

Virus	Cancer
Epstein-Barr virus	Lymphoma
Papilloma virus	Cervical cancer
Hepatitis B virus	Liver cancer
Human T-cell leukemia	T-cell leukemia virus
Herpes virus 8	Kaposi sarcoma
Polyoma virus	Merkel carcinoma

63

## HPV AND CERVICAL CANCER






Harald zur Hausen, MD Nobel Prize, 12/2008



#### HPV vaccine ages 15-26:

- lowers HPV by >85%
- lowers CIN by 99% at 5 yr follow-up

Issue: participation two doses By age 26: Australia 80%; USA 60%




## EPIC: European Prospective Investigation into Cancer and Nutrition


- Obesity: Increased breast, colon cancer
- Mediterranean diet: No effect on cancer
- · Vitamin supplements: No effect on cancer
- · Alcohol: Slight increase in liver and breast cancer
- Dietary fiber: Less colon cancer
- Cured meats: More colon cancer

CANCER CHEMOPREVENTION CLINICAL TRIALS		
	Natural substances	
	Vitamins A, E: Colon cancer in post-menopausal women	
	Result: <i>No change</i> <i>Beta-carotene and vitamin A:</i> Lung cancer in smokers Result: <i>Increased cancer</i>	
	Drugs	
	<i>Finasteride:</i> Prostate cancer in men over 55 <b>at risk</b>	
	Result: 25% reduction Tamoxifen, raloxifene: Breast cancer in women <b>at risk</b> Result: 50% reduction	

### **CANCER IN PRIMARY CARE**

- A. The war on cancer
- B. Cancer screening
- C. Cancer prevention
- D. Cancer survivorship







### **CANCER SURVIVORSHIP**

Primary care practitioners: Screening

Oncologists, etc.: Diagnosis, treatment

Primary care practitioners: Survivorship





• Treatment plan: Adapted to EHR

